ABM Therapeutics receives FDA orphan drug status for GBM therapy

03 Aug 2023
www.pharmaceutical-technology.com
Phase 1Clinical ResultOrphan Drug
ABM Therapeutics receives FDA orphan drug status for GBM therapy
Preview
Source: Pharmaceutical Technology
GBM is a hard-to-treat and extremely aggressive brain tumour. Credit: create jobs 51 / Shutterstock.com.
ABM Therapeutics has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for ABM-1310 to treat patients with glioblastoma (GBM) harbouring the BRAF V600 mutation.
A small-molecule BRAF inhibitorBRAF inhibitor, ABM-1310 is an orally administered medicine with high BRAF mutation selectivity, blood-brain barrier permeability and water solubility.
Recommended Reports
ABM Therapeutics receives FDA orphan drug status for GBM therapy
Preview
Source: Pharmaceutical Technology
ReportsClostridium difficile Toxin B (toxB or EC 3.4.22.) Drugs in Development by Therapy Areas and Indi... GlobalData
ABM Therapeutics receives FDA orphan drug status for GBM therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Drug For Autism And Dementia in Autism Spectrum Disorder (ASD) GlobalData
View allCompanies IntelligenceABM CorporationGBM SRLABM Therapeutics IncView all
The inhibitor is currently in Phase I trials at clinical sites in China and the US, targeting advanced solid tumours with the BRAF V600 mutation.
Interim results from the US Phase I trial showed that ABM-1310 exhibited promising anti-cancer activity and a good safety profile in patients with advanced solid tumours, including primary brain tumours such as GBM and other gliomas.
In China, a new Phase I clinical study focused specifically on GBM has recently commenced.
GBM is a hard-to-treat and extremely aggressive brain tumour. Its treatment remains a significant challenge owing to tumorigenesis complexities and resistance to the therapy.
Traditional treatments such as surgical resection, radiation therapy and chemotherapy have limitations.
ABM Therapeutics, a clinical-stage biopharmaceutical company, focuses on small molecule research and the development of new medicines to treat cancer, specifically brain cancer and brain metastases from solid tumours.
ABM has been developing a pipeline for the construction of a brain medicine research and development platform known as BPKdd. The pipeline comprises several programmes at different stages of discovery and development.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.